147 related articles for article (PubMed ID: 17949554)
1. Infliximab treatment-induced formation of autoantibodies is common in Behçet's disease.
Elezoglou A; Kafasi N; Kaklamanis PH; Theodossiadis PG; Kapsimali V; Choremi E; Vaiopoulos G; Sfikakis PP
Clin Exp Rheumatol; 2007; 25(4 Suppl 45):S65-9. PubMed ID: 17949554
[TBL] [Abstract][Full Text] [Related]
2. Autoantibodies in patients with psoriatic arthritis on anti-TNFα therapy.
Viana VS; de Carvalho JF; de Moraes JC; Saad CG; Ribeiro AC; Gonçalves C; Bueno C; Vendramini MB; Bonfá E
Rev Bras Reumatol; 2010; 50(3):225-34. PubMed ID: 21125159
[TBL] [Abstract][Full Text] [Related]
3. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
[TBL] [Abstract][Full Text] [Related]
4. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease.
Beigel F; Schnitzler F; Paul Laubender R; Pfennig S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S
Inflamm Bowel Dis; 2011 Jan; 17(1):91-8. PubMed ID: 20564536
[TBL] [Abstract][Full Text] [Related]
5. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study.
Ferraro-Peyret C; Coury F; Tebib JG; Bienvenu J; Fabien N
Arthritis Res Ther; 2004; 6(6):R535-43. PubMed ID: 15535831
[TBL] [Abstract][Full Text] [Related]
6. Infliximab-induced autoantibodies: a multicenter study.
Vaz JL; Fernandes V; Nogueira F; Arnóbio A; Levy RA
Clin Rheumatol; 2016 Feb; 35(2):325-32. PubMed ID: 26676808
[TBL] [Abstract][Full Text] [Related]
7. Anti-TNF-alpha treatment in rheumatoid arthritis with anti-Ro/SSA antibodies. Analysis of 17 cases among a cohort of 322 treated patients.
Cavazzana I; Bobbio-Pallavicini F; Franceschini F; Bazzani C; Ceribelli A; Bravi E; Zingarelli S; Caporali R; Cattaneo R; Montecucco CM
Clin Exp Rheumatol; 2007; 25(5):676-83. PubMed ID: 18078613
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.
Atzeni F; Sarzi-Puttini P; Dell' Acqua D; de Portu S; Cecchini G; Cruini C; Carrabba M; Meroni PL
Arthritis Res Ther; 2006; 8(1):R3. PubMed ID: 16356192
[TBL] [Abstract][Full Text] [Related]
9. Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab.
Allanore Y; Sellam J; Batteux F; Job Deslandre C; Weill B; Kahan A
Clin Exp Rheumatol; 2004; 22(6):756-8. PubMed ID: 15638051
[TBL] [Abstract][Full Text] [Related]
10. Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet's disease with infliximab.
Iwata D; Namba K; Mizuuchi K; Kitaichi N; Kase S; Takemoto Y; Ohno S; Ishida S
Graefes Arch Clin Exp Ophthalmol; 2012 Jul; 250(7):1081-7. PubMed ID: 22234352
[TBL] [Abstract][Full Text] [Related]
11. Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease.
Nancey S; Blanvillain E; Parmentier B; Flourié B; Bayet C; Bienvenu J; Fabien N
Inflamm Bowel Dis; 2005 Nov; 11(11):986-91. PubMed ID: 16239844
[TBL] [Abstract][Full Text] [Related]
12. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.
Eriksson C; Engstrand S; Sundqvist KG; Rantapää-Dahlqvist S
Ann Rheum Dis; 2005 Mar; 64(3):403-7. PubMed ID: 15297281
[TBL] [Abstract][Full Text] [Related]
13. Autoantibodies in psoriatic patients treated with anti-TNF-α therapy.
Bardazzi F; Odorici G; Virdi A; Antonucci VA; Tengattini V; Patrizi A; Balestri R
J Dtsch Dermatol Ges; 2014 May; 12(5):401-6. PubMed ID: 24797746
[TBL] [Abstract][Full Text] [Related]
14. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
Charles PJ; Smeenk RJ; De Jong J; Feldmann M; Maini RN
Arthritis Rheum; 2000 Nov; 43(11):2383-90. PubMed ID: 11083258
[TBL] [Abstract][Full Text] [Related]
15. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients.
Vallet H; Riviere S; Sanna A; Deroux A; Moulis G; Addimanda O; Salvarani C; Lambert M; Bielefeld P; Seve P; Sibilia J; Pasquali J; Fraison J; Marie I; Perard L; Bouillet L; Cohen F; Sene D; Schoindre Y; Lidove O; Le Hoang P; Hachulla E; Fain O; Mariette X; Papo T; Wechsler B; Bodaghi B; Rigon MR; Cacoub P; Saadoun D;
J Autoimmun; 2015 Aug; 62():67-74. PubMed ID: 26162757
[TBL] [Abstract][Full Text] [Related]
17. The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis.
Arends S; Lebbink HR; Spoorenberg A; Bungener LB; Roozendaal C; van der Veer E; Houtman PM; Griep EN; Limburg PC; Kallenberg CG; Wolbink GJ; Brouwer E
Clin Exp Rheumatol; 2010; 28(5):661-8. PubMed ID: 20822711
[TBL] [Abstract][Full Text] [Related]
18. Anti-interferon alpha antibodies and autoantibodies in patients with Behçet's disease uveitis treated with recombinant human interferon alpha-2a.
Aydinoglu-Candan Ö; Araz-Erşan B; Gul A; Badur S; Tugal-Tutkun I
Graefes Arch Clin Exp Ophthalmol; 2015 Mar; 253(3):457-65. PubMed ID: 25500983
[TBL] [Abstract][Full Text] [Related]
19. Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab.
Elkayam O; Burke M; Vardinon N; Zakut V; Yitzhak RB; Paran D; Levartovsky D; Litinsky I; Caspi D
Autoimmunity; 2005 Mar; 38(2):155-60. PubMed ID: 16040336
[TBL] [Abstract][Full Text] [Related]
20. Induction of autoantibodies during prolonged treatment with infliximab.
Louis M; Rauch J; Armstrong M; Fitzcharles MA
J Rheumatol; 2003 Dec; 30(12):2557-62. PubMed ID: 14719194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
